1. In which patient demographic is liposarcoma more common?

2. Which of the following soft-tissue sarcoma subtypes is resistant to anthracycline-based first-line therapy for advanced disease?

3. What is the expected impact on 6-month progression free survival (PFS) when continuing trabectedin therapy after achieving a response versus reinitiating after evidence of disease progression?

4. Pazopanib is indicated for all of the following soft-tissue sarcoma subtypes, EXCEPT?

5. A 45-year-old male presents with a 10 cm x 7 cm x 3 cm mass, which is diagnosed as low-grade, stage IIB, undifferentiated pleomorphic sarcoma located superficially in the subcutaneous tissues of the proximal portion of the outer thigh. After limb-sparing surgery and observation for 8 months, the tumor returns locally at multiple locations along the resection line. Which of the following chemotherapy regimens is MOST appropriate for patient?

6. All of the following adverse events occur at an increased frequency with doxorubicin/olaratumab combination therapy compared to doxorubicin alone, EXCEPT:

« Return to Activity